You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site.
QUADRA evaluated ZEJULA as treatment in 4th-line+ patients, including those with BRCA– or platinum-resistant disease1
QUADRA was a single-arm, phase 2 trial of patients with advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy (N=463), including HRD+ patients.1,2
Patient Characteristics in the QUADRA Trial (N=463) Were Representative of a Real-World, Late-Line Population2:
27% of patients were 6th line or later
68% of patients were platinum resistant or refractory
The FDA Indication Is for HRD+ Patients (in QUADRA, n=98) With Either1:
BRCA+ tumors regardless of platinum status
BRCA- tumors with genomic instability (GIS+) and had progressed more than 6 months after the last platinum-based chemotherapy
*19% of patients were 6th line or later.
BRCA+, breast cancer susceptibility gene mutated; BRCA-, not BRCA-mutated; GIS, genomic instability score; HRD+, homologous recombination deficiency positive; ORR, overall response rate.